Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

ClinicalTrials.gov ID: NCT04020341

Public ClinicalTrials.gov record NCT04020341. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

Study identification

NCT ID
NCT04020341
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,531 participants

Conditions and interventions

Interventions

  • Gepotidacin Drug
  • Placebo matching nitrofurantoin Drug
  • Nitrofurantoin Drug
  • Placebo matching gepotidacin Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 16, 2019
Primary completion
Nov 29, 2022
Completion
Nov 29, 2022
Last update posted
Jun 21, 2023

2019 – 2022

United States locations

U.S. sites
41
U.S. states
17
U.S. cities
39
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Phoenix Arizona 85051
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site Beverly Hills California 90211-2921
GSK Investigational Site Chula Vista California 91911
GSK Investigational Site La Mesa California 91942
GSK Investigational Site Lomita California 90717
GSK Investigational Site Long Beach California 90806
GSK Investigational Site Northridge California 91324-3331
GSK Investigational Site Northridge California 91324-3528
GSK Investigational Site Palm Springs California 92264
GSK Investigational Site San Diego California 92120
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site Hialeah Florida 33016
GSK Investigational Site Miami Florida 33144
GSK Investigational Site Miami Springs Florida 33166
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Pompano Beach Florida 33060
GSK Investigational Site Atlanta Georgia 30328
GSK Investigational Site Columbus Georgia 31901-2561
GSK Investigational Site Fayetteville Georgia 31204
GSK Investigational Site Wichita Kansas 67226-3007
GSK Investigational Site New Orleans Louisiana 70115
GSK Investigational Site Shreveport Louisiana 71106
GSK Investigational Site Watertown Massachusetts 02472
GSK Investigational Site Dearborn Heights Michigan 48127-3163
GSK Investigational Site Norfolk Nebraska 68701-2669
GSK Investigational Site East Brunswick New Jersey 08816-1407
GSK Investigational Site Albuquerque New Mexico 87109
GSK Investigational Site Endwell New York 13760
GSK Investigational Site Fayetteville North Carolina 28304
GSK Investigational Site Scottdale Pennsylvania 15683
GSK Investigational Site Smithfield Pennsylvania 15478
GSK Investigational Site Clarksville Tennessee 37043-1524
GSK Investigational Site Memphis Tennessee 38120
GSK Investigational Site Arlington Texas 76014
GSK Investigational Site Austin Texas 78705
GSK Investigational Site Corpus Christi Texas 78414
GSK Investigational Site Forney Texas 75126
GSK Investigational Site Houston Texas 77055
GSK Investigational Site Houston Texas 77065-5597

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04020341, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2023 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04020341 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →